Dapagliflozin side effects and adverse reactions

Dapagliflozin (Dapagliflozin) is an SGLT2 inhibitor, mainly used to treat type 22 diabetes. Although dapagliflozin has a significant effect in helping control blood sugar, some side effects and adverse reactions may occur during use. The following is an overview of some common and serious side effects that may occur with dapagliflozin:

Common side effects:

1.Urinary tract infection: The mechanism of action of dapagliflozin will cause an increase in glucose content in the urine, thereby providing a suitable environment for bacterial growth and may increase the risk of urinary tract infection.

2.Ketoacidosis: Dapagliflozin lowers blood sugar levels by causing the body to excrete excess glucose, which may lead to increased fat metabolism in the body and the production of ketone bodies. If ketone bodies accumulate too much, it may cause ketoacidosis, which manifests as nausea, vomiting, abdominal pain and other symptoms.

3.Hypoglycemia: Although the mechanism of dapagliflozin itself does not cause hypoglycemia (low blood sugar), it may increase the risk of hypoglycemia when used in combination with other antidiabetic drugs.

4.Thirsty and polydipsia: Because dapagliflozin excretes excess glucose through urine, patients may feel thirsty and need to increase fluid intake.

5.Increased urine output: The diuretic effect of dapagliflozin may cause increased urine output, which may sometimes affect sleep at night.

Serious side effects and adverse reactions:

1.Deterioration of renal function: The mechanism of action of dapagliflozin will increase glucose excretion in the renal tubules. Long-term use may have an impact on the kidneys, especially in patients with existing renal damage.

2.Hypotension: Dapagliflozin may cause a slight drop in blood pressure, and may increase some uncomfortable symptoms in patients who already have hypotension.

3.Genital site infection: Due to the effects of dapagliflozin, especially women, there may be an increased risk of genital site infection.

4.Increased risk of fractures: Long-term use of SGLT2 inhibitors may increase the risk of fractures, which may be related to the drug's effect on calcium and bone metabolism.

5.Urinary tract cancer: Some studies suggest that use of SGLT2 inhibitors may be associated with an increased risk of urinary tract cancer, although the specific association is still being explored in studies.

Notes:

1.When using dapagliflozin, renal function tests should be performed regularly to ensure the safety of the drug.

2.During the treatment process, pay attention to monitoring blood sugar levels to avoid the occurrence of hypoglycemia.

3.If any adverse reactions or uncomfortable symptoms occur, you should consult a medical professional in time.

In summary, although dapagliflozin is beneficial in the treatment of diabetes, patients should be aware of possible side effects and adverse reactions when using it. Before starting use, you should discuss your medical condition in detail with your doctor to ensure the suitability and safety of the drug. If you experience any unusual symptoms or reactions, you should consult your doctor immediately.

Dapagliflozin has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The domestic price is relatively cheap. Please consult the local hospital pharmacy or medical insurance bureau for specific prices and reimbursement policies.